Discontinuation of Eliquis (Apixaban) for Hematuria
For hematuria in patients on apixaban, discontinue for 2-3 days before any urological procedure or intervention, with the exact duration depending on renal function and bleeding severity. 1
Clinical Context and Risk Stratification
Hematuria represents a high bleeding risk scenario requiring adequate drug clearance before intervention. The management approach must balance:
- Bleeding control: Ensuring minimal residual anticoagulant effect
- Thrombotic risk: Minimizing time off anticoagulation
- Diagnostic urgency: Up to 24% of hematuria cases involve malignancy 2
Specific Discontinuation Protocol
Standard Renal Function (CrCl >50 mL/min)
Stop apixaban 2 days (48 hours) before planned urological procedures 3, 1. This corresponds to:
- Skipping 4 doses of the twice-daily medication
- Allowing approximately 4-5 drug half-lives to elapse
- Achieving <6% residual anticoagulant effect 4
Moderate Renal Impairment (CrCl 30-50 mL/min)
Stop apixaban 3 days (72 hours) before procedures 4, 5. This extended interval accounts for:
- Prolonged drug elimination with reduced renal clearance
- Need for 4-5 half-lives in patients with slower drug metabolism
- Higher baseline bleeding risk
Severe Renal Impairment (CrCl 15-30 mL/min)
Stop apixaban 4 days (96 hours) before high-risk procedures 5. Consider:
- Significantly prolonged drug half-life
- Potential drug accumulation
- Consultation with hematology/nephrology
Conservative Management Without Procedure
For mild to moderate hematuria managed conservatively (catheterization, irrigation, observation):
- Continue apixaban if bleeding is mild and self-limiting 2
- Hold for 1-2 days if bleeding is moderate 2
- Discontinue for 2+ days if bleeding is severe or persistent 6
The FDA label specifies discontinuing apixaban "at least 48 hours prior to elective surgery or invasive procedures with a moderate or high risk of unacceptable or clinically significant bleeding" 6.
Key Clinical Considerations
Bridging Therapy
Bridging with heparin is NOT recommended for apixaban discontinuation 3, 7. The rapid offset kinetics of apixaban (half-life 7-8 hours) make bridging unnecessary and potentially harmful, increasing bleeding risk without reducing thrombotic events.
Timing Verification
The most recent ACC/AHA guidelines 1 clarify that "the number of days is the number of full days before the day of surgery in which the patient does not take any dose." For example, if the last dose is taken at 8 PM and the procedure is at 8 AM two days later, 36 hours will have elapsed—meeting the 2-day requirement.
Resumption After Hemostasis
Restart apixaban 48-72 hours after hemostasis is secured 3, 6. For high bleeding risk procedures like urological interventions:
- Wait minimum 48 hours if bleeding risk is low
- Wait 72 hours if bleeding risk remains high
- Ensure adequate surgical hemostasis before resuming
Common Pitfalls to Avoid
Don't use INR or aPTT to guide timing: These tests are insensitive for apixaban monitoring 7
Don't bridge with LMWH: This increases bleeding risk without benefit 3, 7
Don't delay diagnostic workup: Malignancy must be ruled out regardless of anticoagulation status 2
Don't ignore renal function: Failure to adjust for CrCl <50 mL/min risks inadequate drug clearance 4, 5
Don't restart too early: Premature resumption (before 48 hours) significantly increases bleeding complications 3, 6
Evidence Quality Note
The 2024 ACC/AHA guidelines 1 provide the most current recommendations, supported by the 2022 CHEST guidelines 7 and the PAUSE trial data. The French GIHP guidelines 5 offer the most granular renal function-based protocols. All major guidelines converge on 2-3 days for standard patients with normal renal function.